FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on ATTRibute-CM Phase 3 study results,
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the ...
GlobalData on MSN18h
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $48 from $45 and keeps an Outperform rating on the ...
The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.
Pharma trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback